American Society of Hirudotherapy

NMR-Based Structural Characterization of a Two-Disulfide-Bonded Analogue of the FXIIIa Inhibitor Tridegin: New Insights into Structure-Activity Relationships

Structural biology published in International Journal of Molecular Sciences (2021)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentSalivary PharmacologySchmitz T et al. · International journal of molecular sciences, 2021

Abstract

The saliva of blood-sucking leeches contains a plethora of anticoagulant substances. One of these compounds derived from Haementeria ghilianii, the 66mer three-disulfide-bonded peptide tridegin, specifically inhibits the blood coagulation factor FXIIIa. Tridegin represents a potential tool for antithrombotic and thrombolytic therapy. We recently synthesized two-disulfide-bonded tridegin variants, which retained their inhibitory potential. For further lead optimization, however, structure information is required. We thus analyzed the structure of a two-disulfide-bonded tridegin isomer by solution 2D NMR spectroscopy in a combinatory approach with subsequent MD simulations. The isomer was studied using two fragments, i.e., the disulfide-bonded N-terminal (Lys1-Cys37) and the flexible C-terminal part (Arg38-Glu66), which allowed for a simplified, label-free NMR-structure elucidation of the 66mer peptide. The structural information was subsequently used in molecular modeling and docking studies to provide insights into the structure-activity relationships. The present study will prospectively support the development of anticoagulant-therapy-relevant compounds targeting FXIIIa.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsDisulfidesFactor XIIIaFibrinolytic AgentsHumansIsomerismLeechesMagnetic Resonance ImagingMagnetic Resonance SpectroscopyModels, MolecularMolecular Dynamics SimulationSalivary Proteins and PeptidesStructure-Activity Relationship

Summary

A two-disulfide-bonded isomer of the 66mer FXIIIa-inhibiting leech peptide tridegin from Haementeria ghilianii was analyzed by solution 2D NMR and molecular dynamics, defining its disulfide-bonded N-terminal and flexible C-terminal fragments for structure-based design.

Why This Matters for Hirudotherapy

This study reports the solution NMR structure of a two-disulfide-bonded analogue of tridegin, a 66-mer peptide from the leech Haementeria ghilianii that specifically inhibits blood coagulation factor FXIIIa, using a two-fragment approach combined with molecular dynamics simulations. The work matters for hirudotherapy and the leech secretome because it advances lead optimization of a leech-derived antithrombotic/thrombolytic candidate toward potential therapeutic development targeting FXIIIa. The structural data support molecular modeling and docking studies aimed at understanding structure-activity relationships. The honest caveat is that this is a preclinical biophysical study; it involves no animal or human subjects, no leech therapy, and the therapeutic relevance is prospective—the abstract does not claim clinical efficacy or FDA approval.

Citation

Reference (Vancouver style)

Schmitz T, Paul George AA, Nubbemeyer B, Bäuml CA, Steinmetzer T, Ohlenschläger O, et al. NMR-Based Structural Characterization of a Two-Disulfide-Bonded Analogue of the FXIIIa Inhibitor Tridegin: New Insights into Structure-Activity Relationships. Int J Mol Sci. 2021;22(2):880. doi:10.3390/ijms22020880. PMID: 33477282

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.